The myeloma treatment landscape has seen a lot of progress in the last few years, with several novel therapies emerging, including immunomodulatory imide drugs (IMiDs), monoclonal and bispecific antibodies, and more recently, cereblon E3 ligase modulators (CELMoDs). Targeting resistance to those drugs is an ongoing topic of research, and it is important to learn how to best use these agents to enhance the patient’s immune response and eventually approach a cure. In amyloidosis as well, there is a growing interest in exploring immunotherapeutic strategies such as CAR-T therapy and bispecific antibodies to improve patient outcomes.

In this fascinating episode chaired by Faith Davies, MBBCh, MRCP, MD, FRCPath, of NYU Langone Medical Center, New York, NY, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, and Hearn Jay Cho, MD, PhD, of Mount Sinai Hospital, New York, NY, have a discussion about novel targets in 2022, commenting on IMiD resistance, immunogenic cell death, and novel treatments for amyloidosis. This discussion took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.

The post Harnessing the power of immunotherapy in myeloma and amyloidosis appeared first on VJHemOnc.